LYPD6
Ly6/PLAUR domain-containing protein 6
Also known as: LYPD6_HUMAN, MGC52057
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q86Y78
- Gene
- LYPD6
- Ensembl
- ENSG00000187123
- Chromosome
- 2
- Canonical length
- 171 aa
- Protein class
- Predicted secreted proteins
- Subcellular location
- Cytosol
- Secretome location
- Secreted in other tissues
OverviewNCBI Gene
Members of the LY6 protein family (see SLURP1; MIM 606119), such as LYPD6, have at least one 80-amino acid LU domain that contains 10 conserved cysteines with a defined disulfide-bonding pattern (Zhang et al., 2010 [PubMed 19653121]).[supplied by OMIM, Apr 2010]
Canonical amino-acid sequenceUniProt
171 residues, UniProt reviewed canonical sequence.
>Q86Y78|LYPD6
1 MEPGPALAWL LLLSLLADCL KAAQSRDFTV KDIIYLHPST TPYPGGFKCF TCEKAADNYE
61 CNRWAPDIYC PRETRYCYTQ HTMEVTGNSI SVTKRCVPLE ECLSTGCRDS EHEGHKVCTS
121 CCEGNICNLP LPRNETDATF ATTSPINQTN GHPRCMSVIV SCLWLWLGLM LLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LYPD6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.38
- Highest tissue expression
- 15 nTPM
Expression across tissuesHPA
Tissue
- placenta: 15 nTPM
- gallbladder: 10 nTPM
- breast: 8.7 nTPM
- testis: 7.6 nTPM
- retina: 6.5 nTPM
- hypothalamus: 5.8 nTPM
Single-cell type
- late spermatids: 409 nCPM
- early spermatids: 107 nCPM
- undifferentiated spermatogonia: 79 nCPM
- astrocytes: 63 nCPM
- breast hormone-responsive cells: 63 nCPM
- pituitary stem cells: 60 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- midbrain: 52 nTPM
- thalamus: 34 nTPM
- hypothalamus: 21 nTPM
- amygdala: 17 nTPM
- medulla oblongata: 15 nTPM
- pons: 14 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.48
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.33
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- positive regulation of canonical Wnt signaling pathway
- pyramidal neuron differentiation
- regulation of synaptic plasticity
- visual perception
- hippocampal interneuron differentiation
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of LYPD6 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LYPD6 as an antibody target. Whether an autoantibody or antibody against LYPD6 could matter depends on whether native LYPD6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LYPD6 is annotated at the cell surface, where native LYPD6 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label LYPD6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...